ClinicalTrials.gg
CompletedNCT01006291BEGIN™Updated Feb 9, 2017Results posted

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes

A Phase 3 interventional study of insulin degludec and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 72 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-09.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
687
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
10th of 70
687 · median 384
Started
2009
with 3 others
Phase 3
49 of 70
2 open now
Registered
4th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 4 that started in 2009, is one of 49 in phase 3, and was the 4th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes. Subjects treated with oral antidiabetic drug(s) (OAD(s)) should continue their current OAD treatment at the stable, prerandomisation dose level and dosing frequency.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 687 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months
  • Current treatment: oral anti-diabetic drug(s) (OAD(s)) alone, basal insulin alone or the combination of OAD(s) and basal insulin. Allowed OADs are: Metformin, insulin secretagogues (sulphonylureas (SU) or glinides), pioglitazone with unchanged dosing for at least 3 months prior to Visit 1
  • : OADs only users 7.0-11.0 % (both inclusive), basal insulin with/without OADs users 7.0-10.0% (both inclusive) by central laboratory analysis
  • (BMI) below or equal to 40.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Cancer and medical history of cancer hereof
  • Use within the last 3 months prior to Visit 1 of: glucagon-like peptide-1(GLP-1) receptor agonist (exenatide, liraglutide), rosiglitazone, dipeptidyl peptidase IV (DPP-IV) inhibitors, alpha-glucosidase-inhibitors
  • Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
  • Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)
  • Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate measures according to local requirements
  • Cancer and medical history of cancer hereof (except basal cell skin cancer and squamous cell skin cancer)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
687 participants (actual)

Study arms

  • Experimental
    IDeg OD FF

    Drug: insulin degludec

  • Experimental
    IDeg OD

    Drug: insulin degludec

  • Experimental
    IGlar OD

    Drug: insulin glargine

Interventions

  • Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.

  • Injected s.c. (under the skin) once daily. Dose was individually adjusted.

  • Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change from baseline in HbA1c after 26 weeks of treatment

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)

    Mean of SMPG after 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, before bedtime, at 4 am and before breakfast.

    Time frame: Week 26

  2. Rate of Confirmed Hypoglycaemic Episodes

    Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: Week 0 to Week 26 + 7 days follow up

  3. Rate of Nocturnal Confirmed Hypoglycaemic Episodes

    Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

    Time frame: Week 0 to Week 26 + 7 days follow up

08

Results

Posted Nov 13, 2015

Participant flow

The trial was conducted at 69 sites in 14 countries: Hungary (3 sites), Macedonia (1 site), Serbia (3 sites), Finland (7 sites), Norway (6 sites), United Kingdom (6 sites), Argentina (4 sites), Mexico (2 sites), South Africa (3 sites), India (10 sites), Malaysia (5 sites), Taiwan (3 sites), Russian Federation (8 sites) and Israel (8 sites).

Participant flow — Overall Study
MilestoneIDeg OD FFIDeg ODIGlar OD
Started229228230
Exposed230226229
Completed203204203
Not completed262427
Withdrew: Adverse event212
Withdrew: Lack of efficacy221
Withdrew: Protocol violation333
Withdrew: Withdrawal criteria544
Withdrew: Other141417

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change from baseline in HbA1c after 26 weeks of treatment

Time frame:
Week 0, Week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c)
percentage of glycosylated haemoglobinIDeg OD FFIDeg ODIGlar OD
Change in Glycosylated Haemoglobin (HbA1c)-1.28 ± 1.00-1.07 ± 0.99-1.26 ± 1.07
SecondaryMean of 9-point Self Measured Plasma Glucose Profile (SMPG)

Mean of SMPG after 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, before bedtime, at 4 am and before breakfast.

Time frame:
Week 26
Reported as:
Mean · mmol/L
Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
mmol/LIDeg OD FFIDeg ODIGlar OD
Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)7.9 ± 1.88.0 ± 2.17.8 ± 1.9
SecondaryRate of Confirmed Hypoglycaemic Episodes

Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Rate of Confirmed Hypoglycaemic Episodes
Episodes/100 years of patient exposureIDeg OD FFIDeg ODIGlar OD
Rate of Confirmed Hypoglycaemic Episodes364363348
SecondaryRate of Nocturnal Confirmed Hypoglycaemic Episodes

Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Episodes/100 years of patient exposureIDeg OD FFIDeg ODIGlar OD
Rate of Nocturnal Confirmed Hypoglycaemic Episodes635675

Adverse events

Collected over The adverse events were collected in a time frame of 26 weeks + 7 days follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg OD FF—6/230 (2.6%)58/230 (25.2%)
IDeg OD—8/226 (3.5%)57/226 (25.2%)
IGlar OD—4/229 (1.7%)53/229 (23.1%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventIDeg OD FFIDeg ODIGlar OD
Urinary tract infectionInfections and infestations2/2300/2260/229
AnaemiaBlood and lymphatic system disorders0/2301/2260/229
Myocardial infarctionCardiac disorders0/2301/2260/229
AppendicitisInfections and infestations0/2301/2260/229
Subcutaneous abscessInfections and infestations0/2301/2260/229
HypoglycaemiaMetabolism and nutrition disorders0/2301/2260/229
Hypoglycaemic unconsciousnessMetabolism and nutrition disorders0/2301/2260/229
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2301/2260/229
Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2301/2260/229
Oral neoplasm benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2301/2260/229
Most frequent other events
Most frequent other events
EventIDeg OD FFIDeg ODIGlar OD
NasopharyngitisInfections and infestations23/23020/22618/229
Upper respiratory tract infectionInfections and infestations20/23011/22620/229
HeadacheNervous system disorders16/23016/2269/229
DiarrhoeaGastrointestinal disorders10/23014/22610/229
DizzinessNervous system disorders3/2303/22612/229
Back painMusculoskeletal and connective tissue disorders12/2309/2266/229

Baseline characteristics

Age, Continuous
Age, Continuous(years)IDeg OD FFIDeg ODIGlar ODTotal
Mean56.2 ± 10.356.5 ± 9.656.7 ± 8.856.4 ± 9.6
Gender
Gender(Participants)IDeg OD FFIDeg ODIGlar ODTotal
Female94104119317
Male135124111370
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDeg OD FFIDeg ODIGlar ODTotal
Mean8.5 ± 1.08.4 ± 0.98.4 ± 0.98.4 ± 0.9
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDeg OD FFIDeg ODIGlar ODTotal
Mean9.0 ± 2.68.8 ± 2.89.0 ± 2.88.9 ± 2.7
09

Study locations

72 sites
  • Novo Nordisk Investigational Site
    Buenos Aires, B1636DSU, Argentina
  • Novo Nordisk Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • Novo Nordisk Investigational Site
    Ciudad Autónoma de Bs As, C1426ABP, Argentina
  • Novo Nordisk Investigational Site
    Rosario, 2000, Argentina
  • Novo Nordisk Investigational Site
    Hanko, 10900, Finland
  • Novo Nordisk Investigational Site
    Harjavalta, FI-29200, Finland
  • Novo Nordisk Investigational Site
    Oulu, 90029, Finland
  • Novo Nordisk Investigational Site
    Tampere, FI-33520, Finland
  • Novo Nordisk Investigational Site
    Turku, 20520, Finland
  • Novo Nordisk Investigational Site
    Turku, FI-20100, Finland
  • Novo Nordisk Investigational Site
    Vantaa, FIN-01600, Finland
  • Novo Nordisk Investigational Site
    Budapest, 1041, Hungary
  • Novo Nordisk Investigational Site
    Debrecen, 4043, Hungary
  • Novo Nordisk Investigational Site
    Gyor, 9024, Hungary
  • Novo Nordisk Investigational Site
    Szombathely, H-9700, Hungary
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500082, India
  • Novo Nordisk Investigational Site
    Kochi, Kerala 682041, India
  • Novo Nordisk Investigational Site
    Indore, Madhya Pradesh 452010, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400012, India
  • Novo Nordisk Investigational Site
    New Dehli, New Delhi 110029, India
  • Novo Nordisk Investigational Site
    Chandigarh, Punjab 160012, India
  • Novo Nordisk Investigational Site
    Vellore, Tamil Nadu 632004, India
  • Novo Nordisk Investigational Site
    Kolkata, West Bengal 700020, India
  • Novo Nordisk Investigational Site
    Kolkata, West Bengal 700038, India
  • Novo Nordisk Investigational Site
    Chennai, 600020, India
  • Novo Nordisk Investigational Site
    Hyderabad, 600034, India
  • Novo Nordisk Investigational Site
    Beer Sheva, 84101, Israel
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel
  • Novo Nordisk Investigational Site
    Holon, 58100, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91120, Israel
  • Novo Nordisk Investigational Site
    Kfar Saba, 44281, Israel
  • Novo Nordisk Investigational Site
    Netanya, 42449, Israel
  • Novo Nordisk Investigational Site
    Petah-Tikva, 49100, Israel
  • Novo Nordisk Investigational Site
    Rehovot, 76100, Israel
  • Novo Nordisk Investigational Site
    Skopje, 1000, Macedonia, The Former Yugoslav Republic of
  • Novo Nordisk Investigational Site
    Cheras, 56000, Malaysia
  • Novo Nordisk Investigational Site
    Kota Bharu, Kelantan, 16150, Malaysia
  • Novo Nordisk Investigational Site
    Kuala Lumpur, 59100, Malaysia
  • Novo Nordisk Investigational Site
    Penang, 10459, Malaysia
  • Novo Nordisk Investigational Site
    Putrajaya, 62250, Malaysia
  • Novo Nordisk Investigational Site
    Mexico City, México, D.F. 03300, Mexico
  • Novo Nordisk Investigational Site
    Durango, 34000, Mexico
  • Novo Nordisk Investigational Site
    Monterrey, 64460, Mexico
  • Novo Nordisk Investigational Site
    Gjøvik, NO-2819, Norway
  • Novo Nordisk Investigational Site
    Hamar, 2317, Norway
  • Novo Nordisk Investigational Site
    Hønefoss, 3511, Norway
  • Novo Nordisk Investigational Site
    Oslo, 0586, Norway
  • Novo Nordisk Investigational Site
    Stavanger, 4005, Norway
  • Novo Nordisk Investigational Site
    Tønsberg, 3116, Norway
  • Novo Nordisk Investigational Site
    Kazan, 420064, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 117036, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 119435, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 121356, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 127644, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Peterburg, 190068, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 195257, Russian Federation
  • Novo Nordisk Investigational Site
    Belgrade, 11000, Serbia
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 1829, South Africa
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 2001, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4126, South Africa
  • Novo Nordisk Investigational Site
    Taipei, 100, Taiwan
  • Novo Nordisk Investigational Site
    Taipei, 112, Taiwan
  • Novo Nordisk Investigational Site
    Taipei, 114, Taiwan
  • Novo Nordisk Investigational Site
    Taoyuan, 333, Taiwan
  • Novo Nordisk Investigational Site
    Belfast, BT16 1RH, United Kingdom
  • Novo Nordisk Investigational Site
    Edgbaston, Birmingham, B15 2TH, United Kingdom
  • Novo Nordisk Investigational Site
    Edinburgh, EH4 2XU, United Kingdom
  • Novo Nordisk Investigational Site
    Glasgow, G45 9AW, United Kingdom
  • Novo Nordisk Investigational Site
    Hull, HU3 2JZ, United Kingdom
  • Novo Nordisk Investigational Site
    Ipswich, IP4 5PD, United Kingdom
  • Novo Nordisk Investigational Site
    Londonderry, BT47 6SB, United Kingdom
  • Novo Nordisk Investigational Site
    Swansea, SA6 6NL, United Kingdom
10

References and documents

Publications

  • Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013 Feb;15(2):175-84. doi: 10.1111/dom.12032. Epub 2012 Dec 3. PubMed 23130654 ↗
  • Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging. 2013 Dec;30(12):1009-18. doi: 10.1007/s40266-013-0128-2. PubMed 24170235 ↗
  • Einhorn D, Handelsman Y, Bode BW, Endahl LA, Mersebach H, King AB. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS. Endocr Pract. 2015 Aug;21(8):917-26. doi: 10.4158/EP14523.OR. Epub 2015 Jun 29. PubMed 26121451 ↗
  • Russell-Jones D, Gall MA, Niemeyer M, Diamant M, Del Prato S. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis. 2015 Oct;25(10):898-905. doi: 10.1016/j.numecd.2015.06.005. Epub 2015 Jun 18. PubMed 26232910 ↗
  • Vora J, Seufert J, Solberg H, Kinduryte O, Johansen T, Hollander P. Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials. Diabetes Obes Metab. 2016 Jul;18(7):716-20. doi: 10.1111/dom.12621. Epub 2016 Feb 8. PubMed 26663320 ↗
  • Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI; NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013 Apr;36(4):858-64. doi: 10.2337/dc12-1668. Epub 2013 Jan 22. PubMed 23340894 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 5 years 2 months after primary completion. A results delay was requested in Nov 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2009
First posted
Nov 1, 2009
Start
Nov 2009
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results delay requested
Nov 5, 2010
Results first posted
Nov 13, 2015
Last update
Feb 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01006291
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 1, 2009
Start date
Nov 2009
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Nov 13, 2015
Last update
Feb 9, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Glargine

Start the discussion